Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Outlook Therapeutics (OTLK) halted, news pending
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Plus Therapeutics, Inc. (PSTV) Tops Q3 EPS by 3c
October 20, 2022 4:10 PM EDTPlus Therapeutics, Inc. (NASDAQ: PSTV) reported Q3 EPS of ($0.19), $0.03 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .
For earnings history and earnings-related data on Plus Therapeutics, Inc. (PSTV) click here.
... More